A systematic review and random-effects meta-analysis synthesized routine-care TB outcomes reported in Cameroon. The pooled proportion of treatment success across 27 reports was 78.2% (95% CI: 73.8–82.1). Heterogeneity was substantial (I2 = 98.2%), indicating wide variation between study reports. Pooled mortality was 8.1% (95% CI: 5.5–11.7; 25 reports; I2 = 97.8%). Reported treatment failure was low at 0.9% (95% CI: 0.5–1.4; 26 reports; I2 = 89.1%), while pooled loss to follow-up (LTFU) was 6.8% (95% CI: 5.0–9.1; 26 reports; I2 = 98.6%). The authors reported participant counts tied to these pooled estimates in the source data.
Variation across reports was marked. The high I2 values reflect differences in design, population mix and setting among the included observational studies. The review pooled data from cohorts and cross-sectional reports; the study team used R Statistics for analysis but the source did not detail additional modelling diagnostics in the abstract.
The study team reported clear subgroup differences. Mortality clustered highest in the South-West region (16.2%). Patients coinfected with TB/HIV experienced substantially greater mortality (30.5%) compared with the overall pooled estimate. Pediatric patients had lower reported mortality (5.0%). Treatment success rates also varied: the Littoral region recorded the lowest success proportion (71.1%), while success among TB/HIV coinfected patients was lower (60.8%). By contrast, multidrug-resistant TB (MDR-TB) patients and pediatric patients had higher reported success—MDR-TB success was reported at 89.3%, pediatric success at 86.8%—as documented in the source.
These subgroup contrasts suggest program performance and patient mix differ by region and clinical subgroup. The abstract did not report granular program-level explanations; instead, the authors linked disparities to the documented group-level outcomes.
The authors reported a temporal decline in treatment failure. Pre-2005 reports showed treatment failure around 2.9%, while reports from 2020 onward documented a failure proportion of 0.5%; the change was statistically significant in the source (p < 0.001). This trend implies measurable improvement in the specific outcome of treatment failure over the study period. The abstract did not present time-series modelling details, but the pooled estimates used reported study periods across 1998–2022.
Meta-analysis of adjusted associations identified several consistent predictors of unfavorable TB outcomes. HIV positivity carried an adjusted odds ratio (AOR) of 2.57 (95% CI: 1.86–3.55). Previous TB treatment was associated with higher odds of poor outcomes (AOR 1.99; 95% CI: 1.40–2.84). Male sex showed increased risk (AOR 1.67; 95% CI: 1.45–1.92), and younger age (≤40 years) was associated with higher odds (AOR 1.45; 95% CI: 1.06–1.98). Absence of antiretroviral therapy among coinfected patients was linked to worse outcomes (AOR 1.71; 95% CI: 1.15–2.54).
These pooled AORs were reported in the source and quantify patient-level risk factors that correlated with non-success, death, failure or LTFU across the included studies. The abstract did not include details on how each primary study adjusted for confounders, nor did it list study-by-study covariate sets in the abstract.
The review searched multiple databases including PubMed, Embase, Scopus, Web of Science, African Journals Online and the Cochrane Library, and supplemented searches with Google Scholar and reference screening. Thirty-two observational studies met eligibility: 25 cohort studies and 7 cross-sectional studies, conducted between 1998 and 2022 across six of Cameroon’s ten regions. The source notes that eligible studies reported at least one WHO-defined treatment outcome. The review registration number provided in the manuscript is CRD420261404490. The abstract states that all data are available in the manuscript and supplementary material.
The authors concluded that TB treatment outcomes in Cameroon remain suboptimal: nearly one in five patients did not achieve treatment success, and mortality was particularly high among TB/HIV-coinfected individuals. They recommended strengthening TB/HIV service integration, earlier initiation of antiretroviral therapy for coinfected patients, targeted support for previously treated patients and men, and interventions to improve retention in care.
The review covered studies from six of ten regions and spanned more than two decades; the abstract implies geographic and temporal gaps in routine-care reporting but does not enumerate all methodological limitations in the abstract. The source indicates supplementary material and the main manuscript include full data and methods; readers should consult those sections for study-level quality assessments, inclusion criteria details, and any additional caveats.